Stratified medicine and reimbursement issues

Frontiers in Pharmacology

Volumn 3 OCT, Issue , 2012, Pages

  Fugel, Hans Joerg ^a   Nuijten, Mark ^b   Postma, Maarten ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Ars Accessus Medica   (Netherlands)

Author keywords

Biomarkers; Diagnostics; Health technology assessment; Reimbursement; Stratified medicine

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG RESEARCH; EUROPEAN UNION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PROGRAM DEVELOPMENT; REIMBURSEMENT; SOCIAL MEDICINE; STRATIFIED MEDICINE; UNITED STATES;

EID: 84870758931     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00181     Document Type: Article

References (21)

1. Aspinall, M. (2007). Realizing the promise of personalized medicine. Harv. Bus. Rev. 85, 108-117, 165.
2. Blair, E. D. (2010). Molecular diagnostics and personalized medicine. Per. Med. 7, 143-161.
3. Davis, J. C., Furstenthal, L., Desai, A. A., Norris, T., Sutaria, S., Fleming, E., et al. (2009). The microeconomics of personalized medicine. Nat. Rev. Drug Discov. 8, 279-286.
4. Deverka, P. A., Vernon, J., and McLeod, H. L. (2010). Economic opportu-nities and challenges for pharma-cogenomics. Annu. Rev. Pharmacol. Toxicol. 50, 423-437.
5. Douglas, F. L. (2008). Foreword to Mehta S.S: Commercializing Successful Biomedical Technologies. Cambridge University Press.
6. Garrison, L. P., and Austin, F. (2006). Linking PGx-based diagnostics and drugs. Health Aff. 25, 1281-1290.
7. Garrison, L. P., Veenstra, D. L., Carlson, R. J., Carlson, J., and Meckley, L. (2007). Backgrounder on Pharmacogenomics for the Pharmaceutical and Biotechnology Industries: Basic Science, Future Scenarios, Policy Directions. University of Washington. Available at: https://www.pce.uw.edu
8. Goren,A. (2007). Assessing the Economic Case for Stratified Medicine. Massachusetts Institute of Technology. Available at: cbi@mit.edu
9. Issa, A. (2007). Personalized medicine and the practice of medicine in the 21st century. Mcgill J. Med. 10, 53-57.
10. McCabe, C., Bergmann, L., Bosanquet, N.,Ellis,M.,Enzmann,H.,von Euler, M., et al. (2009). Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann. Oncol. 20, 403-412.
11. Meckley,L.M.,andNeumann,P.(2010). Personalized medicine: factors influencing reimbursement. Health Policy 94, 91-100.
12. Miller, I., Ashton-Chess, J., Spolders, H., Fert, V., Ferrara, J., Kroll, W., et al. (2011). Market access challenges in the EU for high medical value diagnostic tests. Per. Med. 8, 137-148.
13. PCAST. (2008). President's Council of Advisors on Science and Technology. Report. Washington: Priorities for PM, Executive Office.
14. Postma, M., Boersma, C., Vandijck, D., Vegter, S., Le, H. H., and Annemans, L. (2011). HTA in personalized medicine: illustration for cost-effectiveness analysis. Expert Rev. Pharmacoecon. Outcomes Res. 11, 367-369.
15. SACGHS. (2008). US Secretary's Advisory Committee on Genetics, Health, and Society. Report. Bethesda: Realizing the Potential of Pharmacogenomics.
16. Scott, M. G. (2010). When do new biomarkers makes economic sense? Scand. J. Clin. Lab. Invest. 70, 90-95.
17. Seiguer, E. (2007). One Size Fits All? Incentives for R&D of Genomic-Based Therapies. Diss. Harvard University, Cambridge.
18. Trusheim,M. R.,Berndt,E. R.,and Douglas,F. L. (2007). Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293.
19. Tunis, S. (2008). Translating medical innovations with appropriate evidence, diffusion and use of genomic innovation in health and medicine. Workshop Summary 2008. National Academy of Sciences, 25-29. Available at: www.iom.edu
20. Vegter, S., Boersma, C., Rozenbaum, M., Wilffert, B., Navis, G., and Postma, M. J. (2008). Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes. Pharmacoeconomics 26, 569-587.
21. Wong, W. B., Carlson, J. J., Thariani, R., and Veenstra, D. L. (2010). Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28, 1001-1013.